Ballicules › Drugs › Carbamazepine
What it is Sodium-channel-blocking antiepileptic; focal seizures, trigeminal neuralgia, and bipolar mania.
Why this one It remains the reference first-line treatment for trigeminal neuralgia, unlike most other mood stabilizers.
What limits it Strong enzyme induction and autoinduction destabilize combinations and dosing; screen relevant ancestry for HLA-B*1502 and monitor sodium and blood counts.
FDA-approved for
seizures (1968) trigeminal neuralgia (1974) bipolar mania (2004)
Off-label
neuropathic pain alcohol withdrawal
FDA label
Read the full label on DailyMed ↗
BOXED WARNING Serious/fatal dermatologic reactions (SJS/TEN) linked to HLA-B*1502 — screen at-risk (Asian-ancestry) patients; aplastic anemia and agranulocytosis
FDA dosing Population Start Target Max
Epilepsy Adults & children >12 yr 200 mg BID (400 mg/day) 800–1200 mg/day 1000 mg/day (12–15 yr); 1200 mg/day (>15 yr)
Epilepsy Children 6–12 yr 100 mg BID (200 mg/day) 400–800 mg/day 1000 mg/day
Epilepsy Children <6 yr 10–20 mg/kg/day <35 mg/kg/day 35 mg/kg/day
Trigeminal neuralgia Adults 100 mg BID (200 mg/day) 400–800 mg/day 1200 mg/day
Titration Epilepsy: increase at weekly intervals; trigeminal neuralgia: increase up to 200 mg/day using 100 mg every 12 h
Renal Undefined
Hepatic Undefined
Do not exceed 35 mg/kg/day in children <6 yr
Instructions Take with meals Extended-release tablets: swallow whole, do not crush or chew Do not give suspension simultaneously with other liquid medications/diluents Reduce dose gradually; do not discontinue abruptly in epilepsy
Contraindications History of bone marrow depression Known sensitivity to tricyclic compounds (e.g., amitriptyline, imipramine, nortriptyline) MAOIs (concurrently or within 14 days) Coadministration with nefazodone (subtherapeutic nefazodone levels)
Cautions Serious dermatologic reactions (SJS/TEN; HLA-B*1502) Aplastic anemia/agranulocytosis, thrombocytopenia, leukopenia Hyponatremia/SIADH Hepatotoxicity Cardiac conduction disturbances (AV block) Suicidal ideation/behavior (AED class)
Adverse reactions Dizziness Drowsiness Unsteadiness/ataxia Nausea/vomiting Aplastic anemia/agranulocytosis (serious) SJS/TEN (serious) Hepatitis (serious)
Pregnancy Undefined
Lactation Undefined
⚠ BOXED WARNINGS
Serious dermatologic reactions and HLA-B*1502 allele Aplastic anemia and agranulocytosis
Cost, est. cash $5–$150/month
Generic entry 1986
Classes and tags
Clinical profile
Therapeutic safety burden 3 / 4
Overdose danger 3 / 4
Weight-gain liability 1 / 4
Sedation liability 1 / 4
QT / Torsades 0 / 4
Direct muscarinic antagonism 2 / 4
Embryofetal risk 3 / 4
Legacy pregnancy category D
Defining liability Serious rash, aplastic anemia/agranulocytosis, hyponatremia and extensive enzyme induction.
Mechanism of action: Carbamazepine ballicule
Open Carbamazepine in the interactive console ↗
Memory aids: mascots and interaction avatars
“Tiger tail (in the) Car maze” Shredder inDucer
Open Carbamazepine in the interactive console ↗